Abstract
Linezolid has been reported to be associated with thrombocytopenia. However, limited information is available on susceptibility to thrombocytopenia after linezolid usage. We aimed to investigate the risk factors for linezolid-associated thrombocytopenia (LAT). We conducted a retrospective cohort study of patients aged ≥ 18 years who received linezolid for ≥ 5 d during hospitalization in 2019. Information was extracted from electronic medical records. Thrombocytopenia was defined as a platelet count of < 100 × 109/L or a reduction from baseline ≥ 25%. Binary logistic regression and survival analyses were used to evaluate the risk factors for LAT. A total of 98 patients were enrolled. Thrombocytopenia occurred in 53.1% patients, with a median of 9 d after initiation of linezolid. There was no significant difference in the mortality or proportion of platelet transfusions between patients with and without thrombocytopenia. A higher risk of LAT was found in patients who received renal replacement therapy (RRT) (OR 4.8 [1.4–16.4]), or concurrent fluconazole (OR 3.5 [1.2–9.8]). Patients who received RRT (8 vs. 15 d) or concurrent fluconazole (11 vs. 15 d) had a shorter median time to develop thrombocytopenia. Those who simultaneously received RRT and fluconazole had the shortest median of time (6.5 d) and the highest risk of developing thrombocytopenia (87.5%).
Similar content being viewed by others
Introduction
Linezolid, a synthetic oxazolidinone antibiotic, has a fair activity against gram-positive pathogens. Because of its good tissue penetration, linezolid is a key therapeutic choice for nosocomial lung infections and skin or skin structure infections1. An oral bioavailability of 100% makes it easy to adjust for administration. According to the manufacturer’s recommendation2, there is no need to adjust the dose for patients with renal impairment or mild-to-moderate hepatic impairment.
Regarding the safety of linezolid, a variety of adverse effects, such as myelosuppression, peripheral and optic neuropathy, serotonin syndrome, and lactic acidosis have been reported2. In comparator-controlled phase III studies3, diarrhea, nausea, and headaches were frequent adverse effects. Although under longer treatment durations, linezolid-treated patients had a higher potential for lower platelet counts compared to the comparator, the difference was not statistically significant. However, emerging observational studies have demonstrated the thrombocytopenic effect of linezolid4,5,6,7,8,9,10,11,12,13. Depending on different definitions of thrombocytopenia, the incidence of thrombocytopenia ranged from 16.7% to 48.4% in adults treated with intravenous or oral linezolid4,5,6,7,8,9,10,11,12,13.
Although several studies have highlighted the susceptible population of linezolid-associated thrombocytopenia, the results are inconclusive. Possible risk factors including high daily dose per kg4,6, long duration5,8,11,13, renal impairment5,6,7,8,10,11,12,13, and low baseline platelet counts9,11,12 have been reported. One study9 showed that carbapenem combination therapy and low baseline platelet count were significant predictors, and the duration of linezolid administration or renal function had little effect. However, a study conducted by Choi et al.11 revealed that low-dose aspirin was a possible risk factor, and the effect of carbapenem combination therapy was not significant.
More than 60% of patients admitted to the intensive care unit may suffer thrombocytopenia14,15,16. Multiple factors predispose an individual to platelet deficiency, including sepsis, major trauma, and drug exposure14,15,16. Medications that may induce thrombocytopenia are as follows: abciximab15, amiodarone11, aspirin11,15, clopidogrel15, digoxin11, dipyridamole15, eptifibatide15, fluconazole17, haloperidol11, heparin11,14,15,16, oxaliplatin16, piperacillin11,16, rifampin11,16, ticlopidine15, trimethoprim-sulfamethoxazole11,15,16, valproic acid11,15, and vancomycin15,16.
In addition to linezolid, a variety of predisposing factors and drugs may contribute to thrombocytopenia. For clinicians, it is urgent to define a susceptible population to avoid harmful outcomes. Therefore, we conducted an observational study to evaluate the risk factors of linezolid-associated thrombocytopenia. However, whether a patient’s predisposing factors or combination treatment with certain drugs aggregates linezolid-related thrombocytopenia is still inconclusive.
Methods
Study design and population
We designed a retrospective cohort study to investigate the possible risk factors for linezolid-associated thrombocytopenia. Patients ≥ 18 years and hospitalized at the E-Da hospital from January 1, 2019 to December 31, 2019, were recruited into this study. We reviewed the electronic medical records of patients who received linezolid orally or intravenously for ≥ 5 d. All linezolid prescriptions were approved by the infection specialist. Patients with any of the following were excluded: A linezolid treatment duration < 5 d, baseline platelet count < 100 × 109/L, received platelet transfusions within 10 d before the linezolid treatment, platelet count not monitored after starting therapy, had undergone chemotherapy or radiation for malignancy, presence of hematological diseases. Our study adhered to ethical restrictions and was approved by the Institutional Review Board of E-Da Hospital (EMRP-109–142). This observational study was performed by reviewing the medical records and the informed consent was waived by the Institutional Review Board of E-Da Hospital due to analysis of de-identified secondary data and posed no more than minimal risk of harm to study subjects.
Individual characteristics
Individual characteristics and information from hospitalization, including age, sex, body weight, height, comorbidity, history of renal replacement therapy (RRT), date of admission, and date of discharge were collected from the medical information system. Diseases that had been documented in medical records more than three times in 6 months prior to the initiation until the end of therapy were defined as comorbidities. In addition, admission to the intensive care unit during hospitalization, and history of receiving chemotherapy or radiotherapy in the six months prior to initiation until discontinuation of linezolid were also collected.
Information about linezolid usage such as type of infection, route of administration, dosage, and dosing interval were collected from electronic medical records. Previously prescribed glycopeptides, concurrent antibiotics, and combination medications that might affect platelet count and the date of platelet transfusions were reviewed. Combination medications were defined as medications that were co-administrated with linezolid for ≥ 3 d.
Laboratory data
Laboratory data, such as microbiological isolates, platelet count, and serum creatinine, were collected from electronic medical records.
The baseline platelet count was defined as the latest platelet count prior to linezolid treatment. The percentage change in platelet count was calculated by baseline and the lowest platelet count after initiating therapy. According to the latest version of the Common Terminology Criteria for Adverse Events (CTCAE), version 518, thrombocytopenia was defined as a platelet count < 100 × 109/L15 or a reduction from baseline ≥ 25%. Platelet counts that recovered to ≥ 150 × 109/L or baseline, and platelet counts after linezolid discontinuation ≥ 14 d were also collected.
The latest data on serum creatinine levels before initiation of linezolid were collected. Baseline renal function was estimated using the Cockcroft-Gault Equation19. Based on the recommendation from Kidney Disease Improving Outcomes (KDIGO)20, the glomerular filtration rate (GFR) ≥ 90, 60–89, 45–59, 30–44, 15–29, and < 15 mL/min/1.73 m2 are indicated to stage 1, 2, 3a, 3b, 4, and stage 5, respectively. We divided the kidney functions into 4 categories in reference to the guideline of KDIGO20: creatinine clearance (CrCL) ≥ 60 (normal to mild decrease) , 30 ≤ CrCL < 60 (moderate decrease), CrCL < 30 mL/min (severe decrease), and RRT.
Statistical analysis
Continuous and categorical variables were analyzed using the t-test and chi-square test, respectively. For nonparametric variables, the Mann–Whitney U test or Fisher’s exact test was used instead. The association between risk factors and thrombocytopenia was evaluated using binary logistic regression and adjustment for potential confounders. Variables with a P-value < 0.1, in the univariable model were further evaluated in the multivariable model. Analyses were presented as estimates and 95% confidence intervals, and P-values < 0.05, were considered significant. The time between initiating the treatment and the occurrence of thrombocytopenia was analyzed using Kaplan–Meier curves and was tested using the log-rank test. Statistical analyses were performed using SAS version 9.4.
Ethics approval and consent to participate
This study adhered to ethical restriction and was approved by Institutional Review Board of E-Da hospital. Approval number was EMRP-109–142.This observational study was performed by reviewing the medical records and the informed consent was waived by the Institutional Review Board of E-Da Hospital due to analysis of de-identified secondary data and posed no more than minimal risk of harm to study subjects.
Results
A total of 216 patients were prescribed intravenous or oral linezolid in 2019. After excluding 118 patients, 98 patients were finally included in this study (Fig. 1). Table 1 shows the individual characteristics of the 98 study subjects stratified by thrombocytopenia. The mean age of all study subjects was 69.0 ± 15.7 years and was equal in both sexes. Sixty-five patients (66.3%) received intravenous linezolid. The average treatment duration of linezolid was 13.9 ± 7.2 d. Urinary tract infection was observed in 48.0% of patients, and 52.0% of patients had a history of intensive care unit admission. Vancomycin-resistant Enterococcus isolates and oxacillin-resistant Staphylococcus isolates were present in 71.7% and 13.0% of patients, respectively.
Thrombocytopenia occurred in 52 patients (53.1%), with a median of 9 d after initiation of linezolid, and 8 of them (15.4%) received platelet transfusions. After discontinuation, the median duration of platelet counts returned to normal range was 10 d.
There was no significant difference in mortality (26.9% and 23.9%, P = 0.7330) and proportion of platelet transfusions (15.4% and 4.4%, P = 0.0716) between those with and without thrombocytopenia. Patients who developed thrombocytopenia had a significantly higher proportion of patients receiving RRT (36.5% vs. 10.9%), intravenous administration of linezolid (75.0% vs. 56.5%), male (59.6% vs. 39.1%), and longer median duration (14.0 vs. 10.5 d). In addition, a higher ratio of diabetes mellitus, chronic kidney disease, and concurrent use of fluconazole were found in thrombocytopenia (Table 1).
Table 2 shows the odds ratios of the risk factors associated with linezolid-associated thrombocytopenia. In the crude model, patients who were male, diabetic, receiving RRT, intravenous linezolid, or concurrent fluconazole therapy were found to have increased odds ratios of linezolid-associated thrombocytopenia compared with their counterparts. In the main model, we found increased odds ratios of linezolid-associated thrombocytopenia in patients who received RRT, and concurrent fluconazole therapy, with an OR of 4.773 (95% CI 1.390–16.389), and OR 3.474 (95% CI 1.230–9.810), respectively.
Figure 2 illustrates the Kaplan–Meier survival curves of linezolid-associated thrombocytopenia events in patients who received RRT or fluconazole treatment. We found that patients who underwent RRT had a shorter median time (with vs. without RRT: 8 vs. 15 d, log-rank test P = 0.0043; Fig. 2) and higher risk (with vs. without RRT: 79.2% vs. 44.6%, P = 0.0032) of developing linezolid-associated thrombocytopenia. However, there was no significant difference in the incidence of thrombocytopenia between CrCL < 30, 30 ≤ CrCL < 60 and CrCL ≥ 60 mL/min (results detailed in Supplementary Fig. S1). Among the 24 patients who received RRT, 16 (67%) had end-stage renal disease (ESRD) who underwent RRT, while the others underwent emergent RRT for acute kidney injury (AKI). A slightly higher percentage of thrombocytopenia was noted among ESRD patients than among AKI patients, but the difference was not statistically significant (ESRD vs. AKI: 81.25% vs. 75.00%, P = 0.7223).
Patients who received fluconazole were also observed to have a shorter median time (with vs. without fluconazole: 11 vs. 15 d, log-rank test P = 0.0332; Fig. 2) and higher risk (with vs. without fluconazole: 66.7% vs. 45.2%, P = 0.0397) of developing linezolid-associated thrombocytopenia.
Figure 3 illustrates the subgroup analyses of linezolid-associated thrombocytopenia stratified by RRT and fluconazole therapy. The incidence of linezolid-associated thrombocytopenia was 34.8%, 60.7%, 75.0%, and 87.5%, respectively, showing an incremental trend in subgroups without RRT and fluconazole, with fluconazole, with RRT, and with both RRT and fluconazole. Multiple logistic regression showed that the odds ratios were 13.125 (95% CI 1.482–1116.267), 5.625 (95% CI 1.558–20.312), and 2.898 (95% CI 1.097–7.654), respectively, among patients who received concurrent RRT and fluconazole, RRT alone, and fluconazole alone compared with patients who did not receive RRT and fluconazole therapy.
Discussion
To the best of our knowledge, this study is the first to demonstrate that patients who received RRT or concurrent fluconazole treatment may have a higher incidence of linezolid-associated thrombocytopenia. In addition, we revealed the real-world situation and the association between clinical risk factors and linezolid-associated thrombocytopenia.
By performing binary logistic regression, RRT and concurrent fluconazole therapy were identified as risk factors for linezolid-associated thrombocytopenia.
We discovered that patients who received RRT had a significantly higher risk (with vs. without RRT: 79.2% vs. 44.6%, P = 0.0032) and shorter median time (with vs. without RRT: 8 vs. 15 days, P = 0.0043) to have thrombocytopenia. Our finding was compatible with Hanai et al.’s results, which showed an onset time of 8.5 d in patients undergoing hemodialysis8. Hirano et al. found that patients with CrCL < 30 mL/min (60.0%) had a significantly higher incidence of thrombocytopenia then those with CrCL > 60 mL/min (26.4%)5. Moraza et al. and Hanai et al.8reported similar findings7. Several studies have revealed that renal function plays a critical role in thrombocytopenia associated with linezolid5,6,7,8,10,12,21. The manufacturer recommends that the pharmacokinetic parameters of the parent drug are not transformed2, and that no dosage adjustment is needed for renal impairment. However, a higher incidence of thrombocytopenia was noted among our patients who received RRT. Brier et al. concluded that the levels of two primary metabolites (PNU-142586 and PNU-142300) were higher in patients requiring hemodialysis22. Matsumoto et al. suggested that renal impairment elevated linezolid trough concentration, and higher drug exposure might be related to thrombocytopenia23. Considering the higher possibility of thrombocytopenia in renal dysfunction, physicians should be aware of the harmful outcomes, although the mechanism of linezolid-associated remains unclear.
The literature reports fluconazole-associated thrombocytopenia limited to several case reports. Pasikhova et al. reported a case of fluconazole-associated agranulocytosis with thrombocytopenia17. One population-based study enrolled 54,803 users of either fluconazole or itraconazole, and only 1 of 34,220 fluconazole users had thrombocytopenia24. So far, no interaction between fluconazole and linezolid has been found25. Little information is available regarding the underlying fluconazole and linezolid-associated thrombocytopenia. Further studies are necessary.
We found that patients treated with linezolid for ≥ 14 d had a relatively higher frequency of thrombocytopenia (duration ≥ 14 d vs. 14 > duration ≥ 5 d: 63.83% vs. 43.14%, P = 0.0403) (results detailed in Supplementary Fig. S2). Our results are compatible with those of other studies. Hirano et al 5 and Takahashi et al.13 reported a higher incidence of thrombocytopenia among patients with linezolid duration ≥ 14 d. Choi et al. 11 even suggested an increased odds ratio for linezolid duration ≥ 7 d. Therefore, we suggest monitoring platelet counts for prolonged durations of linezolid administration, especially for those who received RRT.
According to recent studies, the incidence of thrombocytopenia ranged from 16.7% to 48.4% in adults treated with linezolid4,5,6,7,8,9,10,11,12,13. Kim et al.10 revealed a 48.3% risk of thrombocytopenia in a cohort of 60 ICU patients, and thrombocytopenia was defined as a platelet count of < 150 × 109/L or a decrease of at least 50% from the baseline. The relatively higher incidence (53.1%) in our study could have resulted from different disease severities and definitions of thrombocytopenia.
Our data showed that patients with diabetes mellitus had twice the risk of thrombocytopenia. However, this was not significant after adjusting for confounding factors. Diabetic kidney disease, a microvascular complication, frequently leads patients to undergo dialysis or renal transplantation26. Consequently, a higher proportion of diabetes mellitus in the thrombocytopenic group is anticipated. Regarding the administration route, IV-form linezolid was used in hospitalized patients, while oral-form linezolid was mostly prescribed for discharge in our study. Therefore, the lower risk of thrombocytopenia for oral-from linezolid in comparison to IV-from linezolid may reflect the different disease severity between discharged and hospitalized patients. Our results were compatible with the findings of Takahashi et al.13.
However, the mechanism underlying linezolid-associated thrombocytopenia remains unclear. Several mechanisms have been proposed. For instance, immune-mediated thrombocytopenia has been proposed by Bernstein et al.27. Other theories, including the suppression of platelets release from mature megakaryocytes28, and Tsuji et al. assumed that the inhibition of the platelet formation was the most common mechanism29. Many studies reported that the linezolid-associated adverse reactions were related to linezolid trough concentration (Cmin)30,31. Cojutti et al.32 monitored patients’ Cmin for dose adjustment at day 3–5 of therapy, and 2–8 mg/L was taken as desired range for Cmin. Peripheral venous blood samples were collected 5 min prior to the subsequent dose. Levels of linezolid were analyzed by a validated HPLC analysis method. However, more studies are necessary to clarify the approach of dose adjustment.
Several clinical factors might also affect platelets, such as a history of surgery and recent transfusions33. Using radionuclides, the mean life span of transfused platelets in humans was 9.9 ± 0.6 d34,35,36,37. Therefore, we excluded patients who received platelet transfusions ≤ 10 d before initiation of linezolid. Moreover, the material of the dialyzer may cause thrombocytopenia; polysulfone membranes and amounts of polyvinylpyrrolidone are thought to be related to its occurrence, but the exact mechanism remains to be elucidated38.
Our observational cohort study has several limitations. First, due to the retrospective nature of the study design, we could not make causal inferences. Second, means of monitoring concentrations of linezolid and its metabolites were not available, and it was difficult to evaluate the pharmacokinetic parameters of linezolid in thrombocytopenic patients. Monitoring linezolid Cmin at steady-state condition may be a feasible approach. However, therapeutic drug monitoring of linezolid is in experimental stage, and more studies are warranted. Third, linezolid is primarily metabolized in liver39, but the value of liver enzymes including aspartate aminotransferase or alanine aminotransferase were not routinely checked for all patients. We used underlying liver disease as a surrogate in the statistic to examine the potential influence of liver function on the relationship of linezolid-related thrombocytopenia. The estimate of liver disease was statistically insignificant in the crude model of logistic regression, and the covariate of liver disease was not further selected in the multivariable model. Fourth, the small sample size of this study may result in the wide ranges of confidence intervals and insignificant statistics for some interested covariates, and the interpretation of our results had to be cautiously.
Conclusions
Renal adjustment is not required for linezolid according to the official recommendation. However, in our study, we found that RRT, and concurrent fluconazole were significantly associated with the risk of thrombocytopenia. Patients who received RRT had a significantly shorter median time to thrombocytopenia after initiation of linezolid. Careful monitoring of platelets is warranted for patients with renal impairment, especially for those already receiving RRT. However, due to the retrospective nature of our study, large randomized control trials are warranted to verify the association between possible clinical factors and the risk of linezolid-associated thrombocytopenia.
Data availability
The datasets analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- AKI:
-
Acute kidney injury
- BMI:
-
Body mass index
- CI:
-
Confidence interval
- CKD:
-
Chronic kidney disease
- CrCL:
-
Creatinine clearance
- CTCAE:
-
Common Terminology Criteria for Adverse Events
- ESRD:
-
End stage renal disease
- ICU:
-
Intensive care unit
- IV:
-
Intravenous
- OR:
-
Odds ratio
- LAT:
-
Linezolid-associated thrombocytopenia
- RRT:
-
Renal replacement therapy
- SD:
-
Standard deviation
- VRE:
-
Vancomycin-resistant enterococcus
References
Dryden, M. S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother. 66(Suppl 4), iv7–iv15. https://doi.org/10.1093/jac/dkr072 (2011).
Product Information: ZYVOX(R) intravenous injection, oral tablets, oral suspension, linezolid intravenous injection, oral tablets, oral suspension., Preprint at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (2020).
Rubinstein, E. et al. Worldwide assessment of linezolid’s clinical safety and tolerability: Comparator-controlled phase III studies. Antimicrob. Agents Chemother. 47, 1824–1831. https://doi.org/10.1128/aac.47.6.1824-1831.2003 (2003).
Niwa, T. et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin. Ther. 31, 2126–2133. https://doi.org/10.1016/j.clinthera.2009.10.017 (2009).
Hirano, R., Sakamoto, Y., Tachibana, N. & Ohnishi, M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int. J. Clin. Pharm. 36, 795–799. https://doi.org/10.1007/s11096-014-9961-6 (2014).
Natsumoto, B., Yokota, K., Omata, F. & Furukawa, K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection 42, 1007–1012. https://doi.org/10.1007/s15010-014-0674-5 (2014).
Moraza, L., Leache, L., Aquerreta, I. & Ortega, A. Linezolid-induced haematological toxicity. Farm. Hosp. 39, 320–326. https://doi.org/10.7399/fh.2015.39.6.8305 (2015).
Hanai, Y. et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J. Infect. Chemother. 22, 536–542. https://doi.org/10.1016/j.jiac.2016.05.003 (2016).
Kaya Kilic, E. et al. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination. J. Infect. Dev. Ctries. 13, 886–891. https://doi.org/10.3855/jidc.10859 (2019).
Kim, H. S., Lee, E., Cho, Y. J., Lee, Y. J. & Rhie, S. J. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study. J. Clin. Pharm. Ther. 44, 84–90. https://doi.org/10.1111/jcpt.12762 (2019).
Choi, G. W. et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin. Pharmacol. Toxicol. 124, 228–234. https://doi.org/10.1111/bcpt.13123 (2019).
Lima, L. S. et al. A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of Brazil. Hematol. Transfus. Cell Ther. 42, 230–237. https://doi.org/10.1016/j.htct.2019.07.004 (2020).
Takahashi, Y. et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J. Infect. Chemother. 17, 382–387. https://doi.org/10.1007/s10156-010-0182-1 (2011).
Zarychanski, R. & Houston, D. S. Assessing thrombocytopenia in the intensive care unit: The past, present, and future. Hematol. Am. Soc. Hematol. Educ. Program 660–666, 2017. https://doi.org/10.1182/asheducation-2017.1.660 (2017).
Ostadi, Z., Shadvar, K., Sanaie, S., Mahmoodpoor, A. & Saghaleini, S. H. Thrombocytopenia in the intensive care unit. Pak. J. Med. Sci. 35, 282–287. https://doi.org/10.12669/pjms.35.1.19 (2019).
Aluru, N. & Samavedam, S. Thrombocytopenia in Intensive Care Unit. Indian J. Crit. Care Med. 23, S185-s188. https://doi.org/10.5005/jp-journals-10071-23249 (2019).
Pasikhova, Y. & Ludlow, S. P. Fluconazole associated agranulocytosis and thrombocytopenia. Int. J. Clin. Pharm. 36, 268–270. https://doi.org/10.1007/s11096-014-9914-0 (2014).
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Preprint at https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (2020).
Cockcroft, D. W. & Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–41. https://doi.org/10.1159/000180580 (1976).
KDIGO. in Kidney Int. Suppl. Vol. 3 1–150 (2012).
Kato, H. et al. Bicytopenia, especially thrombocytopenia in hemodialysis and non-hemodialysis patients treated with linezolid therapy. J Infect Chemother 21, 707–712. https://doi.org/10.1016/j.jiac.2015.06.007 (2015).
Brier, M. E. et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob. Agents Chemother. 47, 2775–2780. https://doi.org/10.1128/aac.47.9.2775-2780.2003 (2003).
Matsumoto, K. et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int. J. Antimicrob. Agents 36, 179–181. https://doi.org/10.1016/j.ijantimicag.2010.02.019 (2010).
Bradbury, B. D. & Jick, S. S. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 22, 697–700. https://doi.org/10.1592/phco.22.9.697.34072 (2002).
Hashemian, S. M. R., Farhadi, T. & Ganjparvar, M. Linezolid: A review of its properties, function, and use in critical care. Drug Des. Devel. Ther. 12, 1759–1767. https://doi.org/10.2147/dddt.S164515 (2018).
Braunwald, E. Diabetes, heart failure, and renal dysfunction: The vicious circles. Prog. Cardiovasc. Dis. 62, 298–302. https://doi.org/10.1016/j.pcad.2019.07.003 (2019).
Bernstein, W. B., Trotta, R. F., Rector, J. T., Tjaden, J. A. & Barile, A. J. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. 37, 517–520. https://doi.org/10.1345/aph.1C361 (2003).
Tajima, M. et al. Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2. Biol. Pharm. Bull. 39, 1846–1851. https://doi.org/10.1248/bpb.b16-00427 (2016).
Tsuji, Y. et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br. J. Clin. Pharmacol. 83, 1758–1772. https://doi.org/10.1111/bcp.13262 (2017).
Nukui, Y. et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J. Antimicrob. Chemother. 68, 2128–2133. https://doi.org/10.1093/jac/dkt133 (2013).
Kawasuji, H. et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol. Toxicol. 22, 13. https://doi.org/10.1186/s40360-021-00479-w (2021).
Cojutti, P. G., Merelli, M., Bassetti, M. & Pea, F. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: Findings from a monocentric, prospective, open-label, interventional study. J Antimicrob. Chemother. 74, 3588–3595. https://doi.org/10.1093/jac/dkz374 (2019).
Gauer, R. L. & Braun, M. M. Thrombocytopenia. Am. Fam. Phys. 85, 612–622 (2012).
Harker, L. A. & Finch, C. A. Thrombokinetics in man. J. Clin. Invest. 48, 963–974. https://doi.org/10.1172/jci106077 (1969).
Davey, R. J. & AuBuchon, J. P. Post-Transfusion Red Blood Cell and Platelet Survival and Kinetics: Basic Principles and Practical Aspects (Elsevier, 2007).
Aster, R. H. Blood platelet kinetics and platelet transfusion. J. Clin. Invest. 123(11), 4564–4565. https://doi.org/10.1172/JCI70335 (2013).
Davey, R. J. & AuBuchon, J. P. Blood Banking and Transfusion Medicine (Elsevier, 2007).
Daugirdas, J. T. & Bernardo, A. A. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int. 82, 147–157. https://doi.org/10.1038/ki.2012.130 (2012).
Stalker, D. J. & Jungbluth, G. L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet. 42, 1129–1140. https://doi.org/10.2165/00003088-200342130-00004 (2003).
Acknowledgements
We would like to thank Lei-Yu Chang for offering help to submit ethics approval and Wan-Yi Chang-Chien for providing assistance on performing statistical analysis.
Funding
This study was not funded by any party.
Author information
Authors and Affiliations
Contributions
Y.C.H. designed the study, reviewed the medical records, collected data, performed the statistical analysis and wrote the manuscript. Y.W.H. designed the study, provided medical opinions and revised the manuscript. S.Y.C. provided statistical assistance and revised the manuscript. Y.J.H. provided hospital resources and related assistance and helped to seek statistical advice. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hsu, YC., Chen, SY., Hung, YJ. et al. Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients. Sci Rep 12, 9894 (2022). https://doi.org/10.1038/s41598-022-13874-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-022-13874-y
- Springer Nature Limited
This article is cited by
-
Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis
European Journal of Clinical Pharmacology (2023)
-
Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis
BMC Pharmacology and Toxicology (2022)